Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

NCT07618546 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT07618546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07618546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Lead sponsor
Henan Cancer Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 25, 2026
Completion date
March 31, 2028
Enrollment
208 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma